prescribing in pregnancy and lactation

in review 4 min read Updated 2026-10-15
prescribing in pregnancy and lactation

Untreated maternal disease is often the bigger foetal risk — don’t stop essential therapy without a substitute. FDA A–X letter categories are retired. Know the short teratogen list, reconcile every medication at delivery (the safe list changes), and check LactMed for breastfeeding. Most drugs are compatible with breastfeeding; codeine, tramadol, DOACs, amiodarone, and cytotoxics are the exceptions to know.

do not miss — established teratogens

ACEi/ARB/ARNI/DRI (T2–T3 fetopathy), warfarin (6–12 wk embryopathy; except mechanical valves), valproate, carbamazepine, phenytoin, topiramate, methotrexate, mycophenolate, leflunomide (washout), cyclophosphamide, isotretinoin, thalidomide/lenalidomide, tetracyclines (after 15 wk), statins (avoid), SGLT2i/GLP-1 RA (no data), DOACs, lithium (Ebstein — modest; continue if needed), radioactive iodine, misoprostol.

pharmacokinetics — what changes dosing

  • ↑ volume of distribution, ↓ albumin → ↑ free fraction (phenytoin: use free level)
  • GFR ↑ ~50% → ↑ clearance of LMWH, levetiracetam, lithium, many antibiotics
  • Hepatic: ↑ CYP3A4, CYP2D6, UGT (lamotrigine ↓↓); ↓ CYP1A2 (caffeine, theophylline ↑)
  • Reverses within 1–3 wk postpartum → dose-reduce LTG, lithium, insulin, β-blockers
  • Placental transfer: small, lipophilic, unbound molecules cross; heparins, insulin, large biologics (until IgG transfer late T3) don’t

by condition

conditionuseavoid / restrict
hypertensionlabetalol, nifedipine XL, methyldopa, hydralazineACEi, ARB, DRI, atenolol, spironolactone
VTE / anticoagulationLMWH, UFH, aspirinDOACs; warfarin except mechanical valves
diabetesinsulin, metformin, glyburideSGLT2i, GLP-1 RA, DPP-4i, other SUs, TZDs
epilepsylamotrigine, levetiracetam, oxcarbazepinevalproate, topiramate, phenytoin/phenobarbital
asthmaICS, ICS–LABA, SABA, montelukast, prednisone, biologicsstopping controllers
thyroidlevothyroxine; PTU in T1 → methimazole from T2radioactive iodine; methimazole in T1 (embryopathy)
autoimmune / IBDhydroxychloroquine (continue), prednisone, azathioprine, sulfasalazine (+ folate), 5-ASA, tacrolimus, cyclosporin, IVIG, colchicine, TNF inhibitorsmethotrexate (stop 1–3 months before), mycophenolate (stop ≥6 wk before), leflunomide (cholestyramine washout), cyclophosphamide, JAK inhibitors
infectionpenicillins, cephalosporins, azithromycin, clindamycin, carbapenems, metronidazole, nitrofurantoin (not near term), vancomycintetracyclines, FQs, TMP-SMX (T1/late T3), aminoglycosides (ototoxicity) unless needed
analgesiaacetaminophen; opioids short-termNSAIDs ≥20 wk (oligohydramnios) and especially ≥28–30 wk (ductus closure)
GIdoxylamine–pyridoxine, dimenhydrinate, metoclopramide, ondansetron, H2RA, PPI, calcium carbonate—
psychiatricSSRIs (continue if needed — sertraline most data), lithium with monitoringparoxetine (cardiac — avoid starting), valproate
opioid use disordercontinue methadone or buprenorphineabrupt withdrawal
  • Hydroxychloroquine in SLE: continue — stopping ↑ flares and worsens pregnancy outcomes
  • Antenatal steroids for foetal lung maturity: betamethasone/dexamethasone; maternal steroids: prednisone/prednisolone (placenta inactivates ~90%)

breastfeeding

classcompatibleavoid / caution
antihypertensiveslabetalol, methyldopa, nifedipine, enalapril, captopril (SOGC); metoprololatenolol (infant bradycardia); ARB, ARNI (no data)
anticoagulantsLMWH, UFH, warfarin, danaparoidDOACs
diabetesinsulin, metformin, glyburideSGLT2i, GLP-1 RA (no data)
analgesiaacetaminophen, ibuprofen (preferred NSAID), short-course morphine/hydromorphonecodeine, tramadol (CYP2D6 ultra-rapid metabolisers → infant opioid toxicity/death)
antiseizurelamotrigine, levetiracetam, carbamazepine, valproatephenobarbital, benzodiazepines (infant sedation)
cardiacmost β-blockers, digoxin, furosemide, spironolactoneamiodarone, ivabradine, statins
othermost antibiotics, SSRIs, HCQ, azathioprine, prednisone, TNF inhibitorslithium (infant levels/TSH — specialist), cytotoxics, radioactive iodine
  • Iodinated and gadolinium contrast: no need to interrupt breastfeeding
  • Oestrogen-containing contraception ↓ milk supply and ↑ VTE <6 wk postpartum → progestin-only/IUD first

postpartum medication reconciliation

  • Insulin: drop below pre-pregnancy dose at placenta delivery
  • Lamotrigine/levetiracetam: taper over 1–3 wk
  • Antihypertensives: escalate day 3–7 (BP peak), wean after; switch to enalapril if proteinuria
  • HF: start full GDMT within breastfeeding limits — peripartum cardiomyopathy
  • Anticoagulation: continue ≥6 wk postpartum where indicated; warfarin acceptable
  • β-blockers for arrhythmia: down-titrate as HR falls
  • Restart drugs stopped for pregnancy (ACEi, statin after breastfeeding)
  • Contraception plan with every teratogen
where to look

LactMed (breastfeeding), MotherToBaby and BUMPS (pregnancy, patient handouts), Reprotox (subscription). UpToDate still shows retired FDA letter categories — don’t use them.


infective endocarditis prophylaxis at delivery

  • Not recommended for vaginal or caesarean delivery, even with high-risk cardiac lesions (ESC/AHA) — standard obstetric surgical prophylaxis still applies
  • Prophylaxis remains for dental procedures in high-risk patients (prosthetic valves/material, prior IE, unrepaired cyanotic CHD) — see infective endocarditis

Prepared 2026-10-15. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction prescribing in pregnancy and lactation